Oramed Pharmaceuticals (ORMP) News Today $2.26 -0.04 (-1.74%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Below 200-Day Moving Average - Should You Sell?Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Crosses Below 200-Day Moving Average - What's Next?November 20 at 3:50 AM | marketbeat.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares Purchased by BML Capital Management LLCBML Capital Management LLC lifted its stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) by 62.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,186,191 shares of the biotecNovember 12, 2024 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Below 200 Day Moving Average - Here's What HappenedOramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Below 200 Day Moving Average - Time to Sell?November 6, 2024 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Buy at StockNews.comStockNews.com upgraded shares of Oramed Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday.October 22, 2024 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Cut to "Hold" at StockNews.comStockNews.com lowered shares of Oramed Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday.October 14, 2024 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to Buy by StockNews.comStockNews.com upgraded Oramed Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Friday.October 4, 2024 | marketbeat.comMurchinson Ltd. Raises Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)Murchinson Ltd. grew its position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) by 23.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,699,990 shares of the biotechnologySeptember 29, 2024 | marketbeat.comMurchinson Ltd. Trims Stock Holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)Murchinson Ltd. decreased its holdings in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) by 36.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 874,992 shares of the biotechnology company's stock aSeptember 24, 2024 | marketbeat.comQ3 2024 EPS Estimates for Oramed Pharmaceuticals Inc. Boosted by Analyst (NASDAQ:ORMP)Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) - Investment analysts at HC Wainwright increased their Q3 2024 earnings per share estimates for Oramed Pharmaceuticals in a report issued on Monday, September 9th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology compaSeptember 11, 2024 | marketbeat.comOramed Pharm (ORMP) Receives a Hold from H.C. WainwrightSeptember 9, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Neutral" Rating for Oramed Pharmaceuticals (NASDAQ:ORMP)HC Wainwright reaffirmed a "neutral" rating on shares of Oramed Pharmaceuticals in a report on Monday.September 9, 2024 | marketbeat.comBrokers Offer Predictions for Oramed Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ORMP)Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) - Investment analysts at Zacks Small Cap cut their Q3 2024 earnings per share estimates for Oramed Pharmaceuticals in a research report issued on Thursday, August 29th. Zacks Small Cap analyst M. Marin now expects that the biotechnology compSeptember 2, 2024 | marketbeat.comORMP: Balance Sheet Strong, Potential Benefits of Investments, JVs, BuybacksAugust 30, 2024 | finance.yahoo.comOramed Pharmaceuticals (NASDAQ:ORMP) Stock Crosses Below 200-Day Moving Average of $2.58Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Below Two Hundred Day Moving Average of $2.58August 24, 2024 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Shares Cross Below 200 Day Moving Average of $2.59Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Cross Below 200-Day Moving Average of $2.59August 16, 2024 | marketbeat.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Large Drop in Short InterestOramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) was the target of a large decline in short interest in the month of July. As of July 15th, there was short interest totalling 334,700 shares, a decline of 36.7% from the June 30th total of 529,100 shares. Based on an average trading volume of 124,200 shares, the days-to-cover ratio is currently 2.7 days.July 26, 2024 | marketbeat.com3 Micro-Cap Moonshots for Fearless InvestorsJuly 8, 2024 | investorplace.comOramed Letter to ShareholdersJune 26, 2024 | prnewswire.comOramed Pharmaceuticals Inc. Announces the Buy-Back of its Common StockJune 26, 2024 | prnewswire.comOramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Below 200 Day Moving Average of $2.55Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Cross Below 200 Day Moving Average of $2.55June 26, 2024 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Below Two Hundred Day Moving Average of $2.54Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Cross Below 200-Day Moving Average of $2.54June 18, 2024 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Below Two Hundred Day Moving Average of $2.54Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Below 200-Day Moving Average of $2.54June 8, 2024 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Shares Cross Below 200 Day Moving Average of $2.53Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Below 200-Day Moving Average of $2.53May 31, 2024 | marketbeat.comORMP: Moving Oral Delivery Platform Forward, + Potential to Generate RoyaltiesMay 29, 2024 | finance.yahoo.comHC Wainwright Weighs in on Oramed Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ORMP)Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) - Analysts at HC Wainwright cut their Q3 2024 EPS estimates for shares of Oramed Pharmaceuticals in a research report issued on Monday, May 20th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earniMay 22, 2024 | marketbeat.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Forecasted to Earn Q1 2025 Earnings of ($0.07) Per ShareOramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) - HC Wainwright issued their Q1 2025 earnings per share estimates for Oramed Pharmaceuticals in a report released on Monday, May 20th. HC Wainwright analyst R. Selvaraju anticipates that the biotechnology company will post earnings per shareMay 21, 2024 | marketbeat.comHC Wainwright Reaffirms "Neutral" Rating for Oramed Pharmaceuticals (NASDAQ:ORMP)HC Wainwright reissued a "neutral" rating on shares of Oramed Pharmaceuticals in a research report on Monday.May 20, 2024 | marketbeat.comOramed Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)May 12, 2024 | finance.yahoo.comORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q1 2024May 10, 2024 | investorplace.comShort Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Declines By 37.0%Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 367,600 shares, a decrease of 37.0% from the March 31st total of 583,900 shares. Based on an average daily volume of 168,800 shares, the days-to-cover ratio is currently 2.2 days.April 27, 2024 | marketbeat.comBML Capital Management LLC Has $2.91 Million Stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)BML Capital Management LLC increased its stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) by 61.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,261,559 shares of the biotecApril 24, 2024 | marketbeat.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Large Growth in Short InterestOramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 583,900 shares, an increase of 20.6% from the March 15th total of 484,000 shares. Based on an average trading volume of 174,600 shares, the short-interest ratio is currently 3.3 days.April 15, 2024 | marketbeat.comORMP Apr 2024 2.500 putMarch 16, 2024 | finance.yahoo.comOramed Pharmaceuticals Full Year 2023 Earnings: Beats ExpectationsMarch 9, 2024 | finance.yahoo.comTrading was temporarily halted for "ORMP" at 09:03 AM with a stated reason of "LULD pause." Trading set to resume at 09:03 AM. March 6, 2024 | marketbeat.comRathbones Group PLC Acquires Shares of 289,803 Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)Rathbones Group PLC bought a new stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 289,803 shares of the biotechnology company's stock, valuedFebruary 22, 2024 | marketbeat.comOramed to reinitiate pivotal type 2 diabetes trial after Phase III flopFebruary 21, 2024 | msn.comOramed Pharmaceuticals Inc.: Oramed Letter to ShareholdersFebruary 20, 2024 | finanznachrichten.deOramed Letter to ShareholdersFebruary 20, 2024 | prnewswire.comORMP: Multiple Potential Applications for Proprietary Oral Protein Delivery PlatformJanuary 24, 2024 | finance.yahoo.comOramed Pharmaceuticals (ORMP) Price Target Increased by 36.51% to 4.39November 28, 2023 | msn.comOramed Pharmaceuticals (ORMP) Price Target Increased by 57.50% to 3.21November 2, 2023 | msn.comOramed Pharmaceuticals (NASDAQ:ORMP) investors are sitting on a loss of 63% if they invested a year agoOctober 6, 2023 | finance.yahoo.comOramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding CompanySeptember 21, 2023 | finance.yahoo.comCorsair Capital Management L.P. Makes New Investment in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)Corsair Capital Management L.P. purchased a new stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 47,256 shares of the biotechnologySeptember 8, 2023 | marketbeat.comOramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology GloballyAugust 2, 2023 | finance.yahoo.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Down 15.1% in JulyOramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a large decrease in short interest in July. As of July 15th, there was short interest totalling 677,000 shares, a decrease of 15.1% from the June 30th total of 797,800 shares. Based on an average trading volume of 869,200 shares, the days-to-cover ratio is presently 0.8 days.July 28, 2023 | marketbeat.comOramed Pharmaceuticals, Inc.July 25, 2023 | jp.reuters.comETF Managers Group LLC Acquires Shares of 68,940 Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)ETF Managers Group LLC acquired a new position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 68,940 shares of the biotechnology company's stock, valued at apprJuly 3, 2023 | marketbeat.comOramed to Present at the 83rd American Diabetes Association ConferenceJune 20, 2023 | finance.yahoo.com Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Email Address The Crypto That’s Making Wall Street Sweat (Ad)The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest. Click here to discover our #1 crypto for the market right now – poised for massive growth ORMP Media Mentions By Week ORMP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORMP News Sentiment▼0.750.45▲Average Medical News Sentiment ORMP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORMP Articles This Week▼10▲ORMP Articles Average Week Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amylyx Pharmaceuticals News Today Alector News Today Ginkgo Bioworks News Today Contineum Therapeutics News Today Kamada News Today Q32 Bio News Today biote News Today SNDL News Today Cryoport News Today AC Immune News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORMP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
